Dr. Drappatz's primary areas of research involve the development of novel agents for the treatment of glioblastoma, central nervous system lymphoma, and other primary and metastatic brain tumors. He has served as the principal investigator of numerous clinical trials to identify effective therapies for patients with brain tumors and other neurological ailments associated with cancer. He is currently leading several clinical trials involving immune therapy, new targeted therapies as well as treatments targeting tumor vasculature. His work has been presented nationally and internationally and has resulted in well over 150 manuscripts, book chapters and abstracts. He serves as a peer reviewer for multiple journals.
Dr. Drappatz is a leading expert in brain cancer treatment and research. As a board-certified neurologist specializing in the field of neuro-oncology. Dr. Drappatz has been the recipient of several awards including Best Doctors, and Castle and Connolly Top Doctors.
Dr. Drappatz received his medical degree from the Johannes Gutenberg University School of Medicine. He completed residency training in neurology at the Partners Neurology Residency Program at Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School, and completed his fellowship training in neuro-oncology at Dana-Farber Cancer Institute.
He is a member of several professional organizations, including the American Association for Cancer Research, American Society of Clinical Oncology, the Society for Neuro-Oncology, the International Primary CNS Lymphoma Collaborative Group, and the “Alliance for Clinical Trials in Oncology” brain tumor committee.
- MD, Johannes Gutenberg University Medical School, 1999
- Residency, Massachusetts General Hospital/Brigham and Women's Hospital, 2004
- Fellowship, Dana Farber Cancer Institute/Massachusetts General Hospital/Brigham & Women's Hospital, 2005
Education & Training
Drappatz J, Wen PY. Chemotherapy and targeted molecular therapies for brain metastases. Expert Review of Neurotherapeutics. 2006; 6(10): 1465-79.
Drappatz J, Batchelor TT. Leptomeningeal neoplasms. Current Treatment Options in Neurology. 2007; 9(4): 283-93.
Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Journal of Neurooncology. 2012; 107(1): 133-8.
Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology Biology Physics. 2010; 78(1): 85-90.
Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Review or Neurotherapeutics. 2009; 9(4): 519-34.
Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, LaFrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceepa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Journal of Radiation Oncology biological physics. 2009; 73(1): 222-7.
Drappatz J. Medical care of patients with brain tumors. Review. 2012; 18(2): 275-94.
Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. Journal of Neuro-oncology. 2013; 115(1): 71-7.
Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Saratopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma. Clinical Cancer Research. 2013; 19(6): 1567-76.
